Intellia Therapeutics Inc (NTLA) - News Archive

Intellia Therapeutics Inc. is set to present compelling longer-term data from its ongoing Phase 1 clinical trial of Nexiguran Ziclumeran (nex-z), an innovative therapeutic approach for treating hereditary transthyretin...

In a notable development concerning the biotechnology sector, Intellia Therapeutics, Inc. (NASDAQ: NTLA) is facing a class action securities lawsuit as announced by the law firm Levi & Korsinsky, LLP. The lawsuit, filed...

Intellia Therapeutics: Strategic Inducement Grants Fuel Growth in CRISPR Gene Editing InnovationIntellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneer in gene editing through CRISPR-based therapies, continues to bolster...

In the fast-paced world of biotechnology, the importance of protecting investor interests cannot be overstated. As the landscape shifts with breakthrough research and corporate developments, the cautionary tales of miss...

In a landscape where innovative medical therapeutics often drive market excitement, Intellia Therapeutics, Inc. (NASDAQ: NTLA) is currently navigating both financial headwinds and potential legal challenges. Rosen Law F...

In the world of investment, legal challenges are often indicative of deeper systemic issues within corporations. Recently, Bragar Eagel & Squire, P.C. a heavyweight in shareholder rights legal action, announced class ac...

Intellia Therapeutics, Inc. (NASDAQ: NTLA), headquartered in Cambridge, Massachusetts, continues to solidify its position as a leader in the clinical-stage gene editing sector. The company, renowned for its cutting-edge...

Intellia Therapeutics Charts Ambitious Course for 2025: Prioritizing Late-Stage Programs and Strengthening Talent for CRISPR InnovationIn a bold move signaling its commitment to advancing groundbreaking gene editing tec...

In a notable development for shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA), the company announced the awarding of inducement grants to three new employees as part of its 2024 Inducement Plan on January 1, 2...

Intellia Therapeutics Amplifies Talent Acquisition with Strategic Inducement GrantsIn the rapidly evolving landscape of biotechnology, talent acquisition is not just a routine human resources operation; it is a strategi...

In a groundbreaking advancement that could redefine the future of genetic medicine, Intellia Therapeutics, Inc. a prominent leader in CRISPR-based therapies, has recently reported promising results from its Phase 1 clin...

Hereditary angioedema (HAE) is a genetic disorder characterized by recurrent episodes of severe swelling in various body parts, including the face, extremities, gastrointestinal tract, and airway. The root cause of HAE...

Pioneering Talent Acquisition: Intellia Therapeutics Expands Workforce to Drive CRISPR InnovationCAMBRIDGE, Mass. - In a strategic move designed to reinforce its commitment to advancing gene editing technology, Intellia...

Intellia Therapeutics has embarked on a significant journey in the realm of gene editing with its lead investigational therapy, nexiguran ziclumeran (nex-z, also known as NTLA-2001). Aimed at treating transthyretin (ATT...

Intellia Therapeutics Gears Up for ACAAI Presentation: Promising Data for NTLA-2002 in Hereditary Angioedema Amid Mixed Financial Performance Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneering entity in the field...

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a prominent player in the clinical-stage gene editing landscape, has recently made strides that promise to revolutionize treatment options for rare genetic disorders. The comp...

Intellia Therapeutics Awards Inducement Grants to Executive Vice President and Chief Financial OfficerIntellia Therapeutics, Inc. (NASDAQ:NTLA), a pioneering clinical-stage gene editing company, revealed earlier this we...

Pioneering Advancements: Intellia Demonstrates Positive Data for Redosing CRISPR Therapy and Long-Term Efficacy in Hereditary Angioedema CAMBRIDGE, Mass., June 25, 2024 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leade...

First-Ever Re-Dosing With Investigational In Vivo CRISPR Therapy: Insights and Implications Intellia Therapeutics has recently presented groundbreaking clinical data on the safety and pharmacodynamics of redosing patien...

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneering clinical-stage genome editing company dedicated to transforming medicine through CRISPR-based therapies, has once again captivated the scientific community with i...